Cathay Biotech Balance Sheet Health
Financial Health criteria checks 5/6
Cathay Biotech has a total shareholder equity of CN¥15.0B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 8.7%. Its total assets and total liabilities are CN¥18.3B and CN¥3.3B respectively. Cathay Biotech's EBIT is CN¥316.0M making its interest coverage ratio -2.4. It has cash and short-term investments of CN¥4.6B.
Key information
8.7%
Debt to equity ratio
CN¥1.30b
Debt
| Interest coverage ratio | -2.4x |
| Cash | CN¥4.64b |
| Equity | CN¥14.99b |
| Total liabilities | CN¥3.34b |
| Total assets | CN¥18.33b |
Recent financial health updates
Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly
Sep 29
Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet
May 28Recent updates
Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality Issues
Nov 07What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling You
Oct 22Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate Capital
Oct 20Cathay Biotech (SHSE:688065) Seems To Use Debt Quite Sensibly
Sep 29Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding Up
Sep 07There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On Capital
Jun 19Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance Sheet
May 28What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling You
May 07We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish Earnings
May 06Financial Position Analysis
Short Term Liabilities: 688065's short term assets (CN¥6.8B) exceed its short term liabilities (CN¥2.4B).
Long Term Liabilities: 688065's short term assets (CN¥6.8B) exceed its long term liabilities (CN¥966.7M).
Debt to Equity History and Analysis
Debt Level: 688065 has more cash than its total debt.
Reducing Debt: 688065's debt to equity ratio has increased from 6% to 8.7% over the past 5 years.
Debt Coverage: 688065's debt is well covered by operating cash flow (55.1%).
Interest Coverage: 688065 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 12:46 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cathay Biotech Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Junjun Zhu | Haitong International Research Limited |